APA (7th ed.) Citation

Jin, J., Cen, H., Zhou, K., Xu, X., Li, F., Wu, T., . . . Shu, Y. (2021). A phase Ib study of a PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma. Journal of clinical oncology, 39(15_suppl), 7531. https://doi.org/10.1200/JCO.2021.39.15_suppl.7531

Chicago Style (17th ed.) Citation

Jin, Jie, et al. "A Phase Ib Study of a PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma." Journal of Clinical Oncology 39, no. 15_suppl (2021): 7531. https://doi.org/10.1200/JCO.2021.39.15_suppl.7531.

MLA (9th ed.) Citation

Jin, Jie, et al. "A Phase Ib Study of a PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma." Journal of Clinical Oncology, vol. 39, no. 15_suppl, 2021, p. 7531, https://doi.org/10.1200/JCO.2021.39.15_suppl.7531.